CLD-101, a stem cell-based platform, delivers oncolytic viruses to tumors, targeting high-grade glioma in a phase 1b/2 trial. Previous trials demonstrated CLD-101's safety and potential efficacy, with ...

The genes encoding IDH1/2 and BRAF are frequently altered in low-grade glioma; the presence or absence of these alterations should be determined in all patients. Maximal safe tumor resection remains ...

Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, primarily depending on clinical trials. Epigenetic agent-based immunotherapy ...

Pediatric gliomas are also known as childhood gliomas. They’re a type of tumor that can develop in a child’s central nervous system (CNS), including their brain or spinal cord. Gliomas are tumors that ...

This study reclassified patients according to modern WHO Classification criteria by integrating multi-dimensional molecular markers. It thoroughly investigated the clinical and molecular disparities ...

Isocitrate dehydrogenase (IDH)-mutant gliomas happen when IDH1 or IDH2 changes create an abnormal enzyme. This mutant enzyme makes D-2 hydroxyglutarate (D-2HG), which encourages tumor growth.